Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.

Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D.

J Immunother Cancer. 2018 Aug 31;6(1):83. doi: 10.1186/s40425-018-0393-z.

2.

Retrospective study of nivolumab for patients with recurrent high grade gliomas.

Mantica M, Pritchard A, Lieberman F, Drappatz J.

J Neurooncol. 2018 Sep;139(3):625-631. doi: 10.1007/s11060-018-2907-4. Epub 2018 May 19.

PMID:
29779086
3.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Sep 3;20(10):1411-1418. doi: 10.1093/neuonc/noy054.

4.

Chemotherapy of Oligodendrogliomas.

Drappatz J, Lieberman F.

Prog Neurol Surg. 2018;31:152-161. doi: 10.1159/000467376. Epub 2018 Jan 25.

PMID:
29393183
5.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH.

Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2. No abstract available.

PMID:
29208433
6.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY.

Neuro Oncol. 2018 Jan 22;20(2):259-267. doi: 10.1093/neuonc/nox151.

7.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF.

Neuro Oncol. 2018 Jan 22;20(2):249-258. doi: 10.1093/neuonc/nox154.

8.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

9.

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators.

Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.

10.

Neuro-oncology family caregivers' view on keeping track of care issues using eHealth systems: it's a question of time.

Boele FW, van Uden-Kraan CF, Hilverda K, Weimer J, Donovan HS, Drappatz J, Lieberman FS, Verdonck-de Leeuw I, Sherwood PR.

J Neurooncol. 2017 Aug;134(1):157-167. doi: 10.1007/s11060-017-2504-y. Epub 2017 May 26.

11.

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY.

J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. Epub 2017 Jan 23.

12.

[18F]ML-10 PET: Initial Experience in Glioblastoma Multiforme Therapy Response Assessment.

Oborski MJ, Laymon CM, Lieberman FS, Qian Y, Drappatz J, Mountz JM.

Tomography. 2016 Dec;2(4):317-324. doi: 10.18383/j.tom.2016.00175.

13.

Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary report.

Boele FW, Given CW, Given BA, Donovan HS, Schulz R, Weimer JM, Drappatz J, Lieberman FS, Sherwood PR.

Cancer. 2017 Mar 1;123(5):832-840. doi: 10.1002/cncr.30428. Epub 2016 Oct 27.

14.

Response of relapsed central nervous system hairy cell leukemia to vemurafenib.

McDowell MM, Zhu X, Agarwal N, Nikiforova MN, Lieberman FS, Drappatz J.

Leuk Lymphoma. 2016 Dec;57(12):2952-2954. Epub 2016 Apr 27. No abstract available.

PMID:
27116997
15.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, Ruland SF, Pulverenti J, Smith KH, Gaffey SC, Hammond S, Wen PY.

Neuro Oncol. 2016 Jun;18(6):849-54. doi: 10.1093/neuonc/now007. Epub 2016 Feb 21.

16.

Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.

Nikiforova MN, Wald AI, Melan MA, Roy S, Zhong S, Hamilton RL, Lieberman FS, Drappatz J, Amankulor NM, Pollack IF, Nikiforov YE, Horbinski C.

Neuro Oncol. 2016 Mar;18(3):379-87. doi: 10.1093/neuonc/nov289. Epub 2015 Dec 17.

17.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

18.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.

Neuro Oncol. 2015 Jun;17(6):862-7. doi: 10.1093/neuonc/nou350. Epub 2015 Jan 7. Erratum in: Neuro Oncol. 2015 Dec;17(12):1650.

19.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY.

Neurology. 2015 Jan 20;84(3):280-6. doi: 10.1212/WNL.0000000000001153. Epub 2014 Dec 19.

20.

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.

Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT.

J Neurooncol. 2015 Feb;121(3):627-34. doi: 10.1007/s11060-014-1680-2. Epub 2014 Dec 13.

21.

Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS.

Clin Cancer Res. 2015 Jan 15;21(2):286-94. doi: 10.1158/1078-0432.CCR-14-1790. Epub 2014 Nov 25.

22.

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.

Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D.

Invest New Drugs. 2015 Feb;33(1):247-53. doi: 10.1007/s10637-014-0186-2. Epub 2014 Nov 13.

PMID:
25388940
23.

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A.

Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6.

24.

Short-T2 imaging for quantifying concentration of sodium (23 Na) of bi-exponential T2 relaxation.

Qian Y, Panigrahy A, Laymon CM, Lee VK, Drappatz J, Lieberman FS, Boada FE, Mountz JM.

Magn Reson Med. 2015 Jul;74(1):162-174. doi: 10.1002/mrm.25393. Epub 2014 Jul 30.

25.

First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.

Oborski MJ, Laymon CM, Lieberman FS, Drappatz J, Hamilton RL, Mountz JM.

Brain Behav. 2014 Mar;4(2):312-5. doi: 10.1002/brb3.217. Epub 2014 Feb 12.

26.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

27.

Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.

Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J.

J Neurooncol. 2013 Oct;115(1):71-7. doi: 10.1007/s11060-013-1196-1. Epub 2013 Jul 5.

PMID:
23828279
28.

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.

Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY.

Neuro Oncol. 2013 Jul;15(7):930-5. doi: 10.1093/neuonc/not040. Epub 2013 Apr 3.

29.

Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article.

Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S.

J Neurosurg. 2013 Jun;118(6):1183-7. doi: 10.3171/2013.1.JNS12397. Epub 2013 Mar 1.

PMID:
23451905
30.

Phase I study of GRN1005 in recurrent malignant glioma.

Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY.

Clin Cancer Res. 2013 Mar 15;19(6):1567-76. doi: 10.1158/1078-0432.CCR-12-2481. Epub 2013 Jan 24.

31.

High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.

Gandhi L, Drappatz J, Ramaiya NH, Otterson GA.

J Thorac Oncol. 2013 Jan;8(1):e3-5. doi: 10.1097/JTO.0b013e3182762d20. No abstract available.

32.

A phase II trial of oral gimatecan for recurrent glioblastoma.

Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F.

J Neurooncol. 2013 Feb;111(3):347-53. doi: 10.1007/s11060-012-1023-0. Epub 2012 Dec 12.

PMID:
23232808
33.

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE.

Blood. 2013 Jan 31;121(5):745-51. doi: 10.1182/blood-2012-07-440974. Epub 2012 Nov 29.

34.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY.

Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24.

35.

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY.

Clin Cancer Res. 2012 Nov 1;18(21):6032-9. doi: 10.1158/1078-0432.CCR-12-1841. Epub 2012 Aug 24.

36.

Medical care of patients with brain tumors.

Drappatz J.

Continuum (Minneap Minn). 2012 Apr;18(2):275-94. doi: 10.1212/01.CON.0000413658.04680.74. Review.

PMID:
22810127
37.

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.

Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A; North American Brain Tumor Consortium.

Leuk Lymphoma. 2013 Jan;54(1):58-61. doi: 10.3109/10428194.2012.698736. Epub 2012 Jul 9.

38.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

39.

Atypical and anaplastic meningiomas treated with bevacizumab.

Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ.

J Neurooncol. 2012 Aug;109(1):187-93. doi: 10.1007/s11060-012-0886-4. Epub 2012 Apr 29.

PMID:
22544653
40.

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY.

J Neurooncol. 2012 Mar;107(1):133-8. doi: 10.1007/s11060-011-0717-z. Epub 2011 Oct 8.

PMID:
21984064
41.

Phase II study of GleevecĀ® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS.

J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22.

42.

Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review.

Moazzam AA, Drappatz J, Kim RY, Kesari S.

J Neurooncol. 2012 Jan;106(1):185-200. doi: 10.1007/s11060-011-0636-z. Epub 2011 Jul 17.

PMID:
21769650
43.

Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.

Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, Batchelor TT, LaCasce AS, Fisher DC, Abramson JS, Armand P, Chen YB.

Biol Blood Marrow Transplant. 2012 Jan;18(1):76-83. doi: 10.1016/j.bbmt.2011.07.006. Epub 2011 Jul 13.

44.

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.

Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY.

J Neurooncol. 2012 Jan;106(1):121-5. doi: 10.1007/s11060-011-0642-1. Epub 2011 Jun 26.

PMID:
21706358
45.

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.

Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY.

J Neurooncol. 2011 Aug;104(1):287-91. doi: 10.1007/s11060-010-0489-x. Epub 2010 Dec 14.

PMID:
21153679
46.

Longitudinal MRI evidence for decreased survival among periventricular glioblastoma.

Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S.

J Neurooncol. 2011 Aug;104(1):261-9. doi: 10.1007/s11060-010-0477-1. Epub 2010 Dec 5.

47.

A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.

Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF; North American Brain Tumor Consortium.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1422-7. doi: 10.1016/j.ijrobp.2010.07.1997. Epub 2010 Oct 8.

48.

Recurrent high-grade glioma.

Quant EC, Drappatz J, Wen PY, Norden AD.

Curr Treat Options Neurol. 2010 Jul;12(4):321-33. doi: 10.1007/s11940-010-0078-5.

PMID:
20842591
49.

Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis.

Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH.

J Neurooncol. 2011 May;103(1):137-46. doi: 10.1007/s11060-010-0365-8. Epub 2010 Sep 14.

PMID:
20838854
50.

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.

Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT.

J Neurooncol. 2011 Jun;103(2):325-32. doi: 10.1007/s11060-010-0390-7. Epub 2010 Sep 7.

Supplemental Content

Loading ...
Support Center